BMC Cancer最新文献

{"title":"A novel serum protein biomarker for the late-stage diagnosis of nasopharyngeal carcinoma.","authors":"Yi-Xi Pan, Qi Huang, Shan Xing, Qian-Ying Zhu","doi":"10.1186/s12885-025-13958-8","DOIUrl":"https://doi.org/10.1186/s12885-025-13958-8","url":null,"abstract":"<p><strong>Background: </strong>Nasopharyngeal carcinoma (NPC) is a malignant tumor prevalent in Southern China, strongly associated with Epstein-Barr virus (EBV) infection. Accurate diagnosis is critical in determining treatment strategies for NPC. In clinical practice, imaging techniques are the most predominant diagnostic methods, which are costly and may fail to detect small metastatic lesions. Moreover, while EBV antibody and DNA tests contribute to the assessment of tumor progression, they carry the risk of false negatives.</p><p><strong>Methods: </strong>To develop novel serum protein biomarkers for late-stage NPC diagnosis, our study included 189 samples, including healthy controls (HCs) and early- or late-stage NPC patients. A high-throughput serum proteomics approach was employed to delineate protein profiles, followed by enzyme-linked immunosorbent assay (ELISA) validation of candidate biomarkers.</p><p><strong>Results: </strong>Our study identified fibronectin 1 (FN1) as a promising serum biomarker for late-stage NPC. The serum levels of FN1 significantly decreased with tumor progression, achieving AUCs of 0.71 and 0.72 in differentiating late-stage NPC patients from HCs and early-stage NPC patients, respectively. Importantly, FN1 demonstrated diagnostic utility in challenging cases, accurately identifying all VCA-IgA-negative and 88.2% EBV DNA-negative patients with late-stage NPC. Combining FN1 with VCA-IgA or EBV DNA test significantly increased diagnostic sensitivity for advanced NPC.</p><p><strong>Conclusions: </strong>Our discovery of FN1 as a biomarker for the late-stage diagnosis of NPC will assist in clinical treatment decisions and improve the prognosis of patients.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"585"},"PeriodicalIF":3.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiotherapy is enhanced by CPH:SA IL-1α microparticles in a murine HNSCC tumor model.","authors":"M M Hasibuzzaman, Rui He, Ishrat Nourin Khan, Aliasger K Salem, Andrean L Simons","doi":"10.1186/s12885-025-13995-3","DOIUrl":"https://doi.org/10.1186/s12885-025-13995-3","url":null,"abstract":"<p><strong>Background: </strong>Radiotherapy (RT) can trigger immunogenic cell death which may be exploited to improve the effectiveness of immunotherapy. However, recent results from clinical trials testing RT/immunotherapy combinations in head and neck squamous cell carcinoma patients (HNSCC) have been disappointing. Interleukin-1 alpha (IL-1α) is a cytokine that can activate various aspects of anti-tumor immunity including dendritic cell (DC) activation which is critical for the recruitment of tumor infiltrating lymphocytes. Here we test the cytokine IL-1α encapsulated in 20:80 1,6-bis-(p-carboxyphenoxy)-hexane:sebacic acid (CPH:SA) copolymer-based microparticles (IL-1αMPs) as an adjuvant to RT in a murine syngeneic HNSCC mouse model. Thus the main research objective of this current study was to evaluate if IL-1αMPs can enhance the antitumor immune response of radiotherapy.</p><p><strong>Methods: </strong>Activation of immune cells in response to RT ± human recombinant IL-1α was evaluated in human peripheral blood mononuclear cell (PBMC):cancer cell co-cultures. A bilateral HNSCC tumor syngeneic mouse model was used to monitor mEERL tumor growth and immune cell recruitment in response to RT (8 Gy to irradiated tumor only) with and without intraperitoneal delivery of IL-1αMPs.  RESULTS: Results showed that IL-1α induced the activation of monocytes, NK cells, T cells, and DCs in PBMC:Cal-27 cell co-cultures but there was no enhanced immune cell activation (with the exception of NK cells) in vitro when combined with RT. RT and RT + IL-1αMPs significantly suppressed growth in irradiated mEERL tumors compared to control. However, only the combination therapy was able to slowdown growth of the non-irradiated tumors compared to the other treatment groups. Immune cell profiling revealed that RT caused acute lymphodepletion on treatment day 3 which was reversed by treatment day 11 in RT-exposed mice. The anti-tumor effect of RT + IL-1α was accompanied by significantly increased infiltration of DCs in the irradiated tumor and increased CD8 + and antigen (E7)-specific CD8 + T cell infiltration in both irradiated and non-irradiated tumors. The anti-tumor response of the combination therapy was completely abrogated by CD8 + T cell depletion.</p><p><strong>Conclusions: </strong>This data suggests that the addition of CPH:SA IL-1αMPs to RT may boost anti-tumor immune response and target both local and systemic disease. This combination is worthy of further investigation as an immunotherapeutic strategy and could represent a promising approach to improve survival outcomes in HNSCC patients.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"588"},"PeriodicalIF":3.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DCE-MRI radiomics of primary breast lesions combined with ipsilateral axillary lymph nodes for predicting efficacy of NAT.","authors":"Yiyao Sun, Qingxuan Liao, Ying Fan, Chunxiao Cui, Yan Wang, Chunna Yang, Yang Hou, Dan Zhao","doi":"10.1186/s12885-025-14004-3","DOIUrl":"https://doi.org/10.1186/s12885-025-14004-3","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to assess the predictive value of radiomic analysis derived from primary lesions and ipsilateral axillary suspicious lymph nodes (SLN) on dynamic contrast-enhanced MRI (DCE-MRI) for evaluating the response to neoadjuvant therapy (NAT) in early high-risk and advanced breast cancer (BC) patients.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 222 BC patients (192 from Center I and 30 from Center II) who underwent NAT. Radiomic features were extracted from the primary lesion (intra- and peritumoral regions) and ipsilateral axillary SLN to develop radiomic signatures (RS-primary, RS-SLN). An integrated signature (RS-Com) combined features from both regions. Feature selection was performed using correlation analysis, the Mann-Whitney U test, and least absolute shrinkage and selection operator (LASSO) regression. A diagnostic nomogram was constructed by integrating RS-Com with key clinical factors. Model performance was evaluated using receiver operating characteristic (ROC) and decision curve analysis (DCA).</p><p><strong>Results: </strong>RS-Com demonstrated superior predictive performance compared to RS-primary and RS-SLN alone. The DeLong test confirmed that axillary SLNs provide supplementary information to the primary lesion. Among clinical factors, N staging and HER2 status were significant contributors. The nomogram, integrating RS-Com, N staging, and HER2 status, achieved the highest performance in the training (AUC: 0.926), validation (AUC: 0.868), and test (AUC: 0.839) cohorts, outperforming both the clinical models and RS-Com alone.</p><p><strong>Conclusion: </strong>Radiomic features from axillary SLNs offer valuable supplementary information for predicting NAT response in BC patients. The proposed nomogram, incorporating radiomics and clinical factors, provides a robust tool for individualized treatment planning.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"589"},"PeriodicalIF":3.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143762976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic potential of fusion gene analysis using plasma cell-free RNA in malignant bone and soft tissue tumours.","authors":"Naoki Furukawa, Nobuhiko Hasegawa, Daisuke Kubota, Yasuhiro Nakamura, Hirokazu Tanaka, Shintaro Iwata, Akira Kawai, Tsuyoshi Saito, Tatsuya Takagi, Shinji Kohsaka, Muneaki Ishijima","doi":"10.1186/s12885-025-13950-2","DOIUrl":"https://doi.org/10.1186/s12885-025-13950-2","url":null,"abstract":"<p><strong>Background: </strong>Liquid biopsy, which facilitates minimally invasive analysis of body fluid samples, has considerable potential as a diagnostic and prognostic tool in various cancers. Analysis of circulating tumour cells, circulating tumour DNA, and exosomes in liquid biopsies has advantages and disadvantages. However, their utility in rare cancers, such as malignant bone and soft tissue tumours, remains unknown. In this study, we examined the levels of circulating cell-free tumour RNA (cfRNA) in the blood of patients with malignant bone and soft tissue tumours harbouring specific fusion genes, to explore the relationship between fusion gene expression in the blood and therapeutic response and disease status, and to validate the clinical utility of liquid biopsy.</p><p><strong>Methods: </strong>The study involved 3 cases (7 samples) of Ewing's sarcoma, 6 cases (12 samples) of myxoid liposarcoma, and 1 case (2 samples) of synovial sarcoma with specific fusion genes. Fusion gene analysis was performed using tumour tissue samples to identify breakpoints. Primers for liquid biopsy were designed based on the fusion genes identified. cfRNA was extracted from each patient's plasma and used for reverse transcription polymerase chain reaction (RT-PCR) with the designed primers. The RT-PCR product was subjected to Sanger sequencing.</p><p><strong>Results: </strong>Fusion gene breakpoints were identified in 10 samples from 6 cases. The fusion gene detection rate in the blood was 100% at both naïve status and symptom exacerbation in patients with Stage IV disease. In patients with Stage III disease progressing to Stage IV, the fusion gene was detected in the blood prior to imaging tests.</p><p><strong>Conclusions: </strong>The detection of specific fusion genes from cfRNAs shows potential for monitoring the progression of fusion-related sarcomas in the context of chemotherapy.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"587"},"PeriodicalIF":3.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sweet beverages and the risk of colorectal cancer: the Norwegian Women and Cancer Study.","authors":"Marie Hauan, Charlotta Rylander, Guri Skeie","doi":"10.1186/s12885-025-13835-4","DOIUrl":"https://doi.org/10.1186/s12885-025-13835-4","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer (CRC) is the third most common type of cancer worldwide, with Norwegian women having the highest incidence rate of colon cancer in 2022. The consumption of sweet beverages is a suggested modifiable risk factor for CRC; however, current evidence is limited and inconclusive.</p><p><strong>Objective: </strong>To assess the associations between the intake of sugar-sweetened beverages (SSBs), artificially sweetened beverages (ASBs), and juice and the risk of overall and subsite-specific CRC among Norwegian women.</p><p><strong>Methods: </strong>In this prospective cohort study, we included 73,921 participants aged 41-61 years at baseline. Information on sweet beverage consumption was collected using self-reported food frequency questionnaires at two time points between 1998 and 2014. We used Cox proportional hazards models to estimate hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) for the associations between sweet beverage consumption and the risk of overall CRC, proximal colon cancer, distal colon cancer, and rectal cancer.</p><p><strong>Results: </strong>During a mean follow-up time of 16.5 years from baseline, 1,187 women were diagnosed with CRC. Compared to no consumption, juice consumption was inversely associated with overall CRC risk (HR_{≥ 7 glasses/wk} = 0.81, 95% CI: 0.67-0.98; p-trend = 0.025), colon cancer (HR_{≥ 7 glasses/wk} = 0.73, 95% CI: 0.58-0.94; p-trend = 0.015) and proximal colon cancer (HR_{≥ 7 glasses/wk} = 0.71, 95% CI: 0.52-0.99; p-trend = 0.065) after adjusting for age, education, and diabetes status at baseline. No associations were observed between juice consumption and distal colon cancer or rectal cancer risk, or between the intake of SSBs or ASBs and CRC.</p><p><strong>Conclusion: </strong>We observed no substantial association between the intake of SSBs or ASBs and the risk of CRC or cancer in colorectal subsites in our cohort of Norwegian women. Conversely, our results indicate that juice consumption is associated with a reduced risk of CRC, particularly in the colon. These results warrant further investigation in larger cohorts with power to detect possible differences in cancer risk across colorectal subsites, especially as patterns of sweet beverage consumption are changing.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"592"},"PeriodicalIF":3.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143762616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The relationship between toll-like receptors 9 gene rs5743836 polymorphism and lymphoma risk: a meta-analysis.","authors":"Minchao Yan, Qin Jin, Yan Zhou, Shuping Mo, Lun Tang, Gang Zhang, Qinyan Fu, Hui Zeng","doi":"10.1186/s12885-025-13434-3","DOIUrl":"https://doi.org/10.1186/s12885-025-13434-3","url":null,"abstract":"<p><strong>Objectives: </strong>We performed this meta-analysis to investigate the potential relationship between the polymorphism of the rs5743836 gene of toll-like receptors 9 (TLR9) and the risk of lymphoma.</p><p><strong>Methods: </strong>Statistical analysis of all data was performed using Stata 15.0. Heterogeneity tests for all selected studies were performed using the Chi-square-based Q test (P < 0.05 suggesting heterogeneity) and the I-square test, and the pooled odds ratios (ORs) were calculated. Sensitivity analysis was also performed to evaluate the stability of the pooled results by funnel plot. Begg's regression test was also performed for possible publication bias in three genetic models.</p><p><strong>Results: </strong>We found that the TLR9 gene rs5743836 was significantly associated with the risk of lymphoma in the dominant genetic model (OR = 1.54, 95%CI = 1.03-2.32, P = 0.036). However, we found that the TLR9 gene rs5743836 was not significantly associated with lymphoma risk in the recessive genetic model (OR = 1.04, 95%CI = 0.65-1.65, P = 0.873) and the allele genetic model (OR = 1.28, 95%CI = 0.93-1.76, P = 0.130). We also performed a sensitivity analysis by removing each eligible study, we found that there was no significant change in the merging effect and pooled ORs, which indicates good stability of the results of this study. Publication bias was tested using Begg's funnel plot, and the results suggested that no publication bias was observed in dominant genetic models (TC + CC vs. TT, P = 0.3486), recessive genetic models (CC vs. TC + TT, P = 0.829), and allelic genetic model (C vs. T, P = 0.463).</p><p><strong>Conclusions: </strong>In conclusion, the results of this meta-analysis indicated that the TLR9 gene rs5743836 was significantly associated with lymphoma risk in the dominant genetic model.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"584"},"PeriodicalIF":3.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143762723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of healthcare-associated infection on healthcare services and survival of patients with cancer: a propensity score-matched retrospective study.","authors":"Changpeng Liu, Chunhua Song, Yijie Chen, Xi Li, Yamei Qiao, Xiaowen Zhang, Dongjian Yang, Hongshan Huang","doi":"10.1186/s12885-025-13975-7","DOIUrl":"https://doi.org/10.1186/s12885-025-13975-7","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Healthcare-associated infections (HAI) lead to poor patient outcomes, including morbidity, mortality, length of hospital stay (LOS) and costs. However, limited data exists on the impact of HAI on LOS, cost at different quantiles and the survival of patients with cancer.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To assess the impact of HAIs on LOS, costs, and survival of cancer patients.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This retrospective cohort study used data from January 2017 to December 2018 from a tertiary cancer hospital in Henan. Patient demographic data were sourced from the hospital's electronic medical records. Inclusion criteria were primary cancer diagnoses (ICD codes C00-C97). We balanced the distribution of baseline characteristics between patients with HAI and without using propensity score matching. Quantile regression can estimate how independent variables affect dependent variables at different quantiles. We conducted a quantile regression that assessing the impact of HAI on LOS and costs for patients with cancer and using Kaplan-Meier survival curves to compare the survival.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Our study included 291,535 patients with cancer, among of whom 4,784(1.6%) were diagnosed with HAI and 286,748 were not. Patients with HAI exhibited significantly longer hospital stays, with a mean duration of 26.1 days (range: 17.0 to 40.6 days), compared to their counterparts without HAIs, who had an average stay of 7.2 days (range: 4.0 to 14.0 days) (p &lt; 0.01). Economically, the average hospitalization cost for patients without HAI was $1575.8 (range: 865.6 to 3106.3), substantially lower than the $8710.8 (range: $4073.8 to 13434.0) observed for patients with HAI (p &lt; 0.01). After adjusting for confounders in quantile regression models, HAI was associated with a median increase in LOS of 11.4 (95% confidence interval (CI): 10.9-12.0) days and with excess costs of USD 3449.3 (95% CI: 3281.9-3616.7). The hazard ratio (HR) of death for patients with an HAI was significantly higher than for patients without an HAI (HR: 1.62, 95% CI: 1.50-1.74).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;HAI prolongs the LOS, increases hospital costs, and worsens the survival of patients with cancer compared with other diseases. Our quantile regression results indicate that the impact of HAI on hospitalization costs and LOS is more pronounced among patients with higher baseline costs and longer LOS (e.g., at the 95th percentile). This suggests that patients with more severe conditions or advanced disease stages are more vulnerable to the adverse effects of HAI.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Relevance to clinical practice: &lt;/strong&gt;Targeted surveillance and preventive interventions, such as early infection screening and strict adherence to infection control protocols, should focus on high-risk patients with prolonged LOS and high costs. By preventing infections in these patients, we can more effectively reduce the additional burden of HAI on costs","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"595"},"PeriodicalIF":3.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143762999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of Cancer Associated Fibroblast (CAF) derived miRNAs on head and neck malignancies microenvironment: a systematic review.","authors":"Parsa Golestannejad, Mohamadparsa Monkaresi, Farahnaz Zhian Zargaran, Mohammad Khosravani, Pouya Asgari, Hesam Mobaraki, Mansour Gorjizad, Saina Hasany, Aliakbar Senobari Ghezeljehmeidan, Sara Hemmati, Samaneh Zand, Parsa Ghasemi, Mahsa Asadi Anar","doi":"10.1186/s12885-025-13965-9","DOIUrl":"https://doi.org/10.1186/s12885-025-13965-9","url":null,"abstract":"<p><strong>Background and aim: </strong>MicroRNAs (miRNAs) play a key role in regulating gene expression within the tumor microenvironment, influencing cancer progression and therapy response. Cancer-associated fibroblasts (CAFs) contribute to tumor development by secreting exosomal miRNAs that promote proliferation, invasion, and resistance. This systematic review evaluates the impact of CAF-derived miRNAs on head and neck malignancies.</p><p><strong>Methods: </strong>A systematic search was conducted in PubMed, Scopus, WOS, and Google Scholar following PRISMA guidelines. Studies focusing on CAF-derived miRNAs in head and neck cancers were included. Data extraction covered study characteristics, miRNA profiling methods, functional roles, and clinical significance. The Scirap tool was used for quality assessment.</p><p><strong>Results: </strong>Among 921 identified articles, 21 met the inclusion criteria. Findings indicate that miR-21-5p, miR-106-5p, and miR-196a drive tumor progression in oral squamous cell carcinoma (OSCC), while miR-124 and miR-34a-5p act as suppressors. In esophageal squamous cell carcinoma (ESCC), miR-21 and miR-27a/b contribute to chemotherapy resistance, whereas miR-100-5p inhibits lymphangiogenesis. In head and neck squamous cell carcinoma (HNSCC), miR-196a and miR-196b may serve as diagnostic biomarkers. Exosomal miR-106a-5p promotes nasopharyngeal carcinoma (NPC) metastasis, and miR-7 and miR-196a contribute to therapy resistance in head and neck cancer (HNC).</p><p><strong>Conclusion: </strong>CAF-derived miRNAs significantly influence tumor progression, metastasis, and therapy resistance. These findings highlight their potential as biomarkers and therapeutic targets, warranting further clinical research for personalized treatment strategies.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"582"},"PeriodicalIF":3.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143762532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of ultrasound-guided percutaneous thermal ablation for abdominal wall metastases: a retrospective study.","authors":"Li Han, Xiaoxiao Xie, Min Zhuang, Lu Wang, Xiaobo Wu, Man Lu","doi":"10.1186/s12885-025-13802-z","DOIUrl":"https://doi.org/10.1186/s12885-025-13802-z","url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate the efficacy and safety of ultrasound-guided percutaneous thermal ablation for abdominal wall metastases.</p><p><strong>Materials & methods: </strong>We retrospectively analyzed patients with abdominal wall metastatic nodules who underwent ultrasound-guided microwave ablation (MWA) from August 2018 to September 2024. Tumor volume (V), volume reduction rate (VRR), pain scores, and University of Washington Quality of Life (Uw-QOL) scores were measured at one, three, and six months postoperative.</p><p><strong>Results: </strong>A total of twelve patients were included in the study (8 males and 4 females), with one male patient excluded due to incomplete follow-up data. The median patient age was 51.5 years (range: 37-75). All patients were successfully treated, with no local recurrence noted during follow-up. Tumor volume reduction rates were 45.4%, 76.9%, and 96% at one, three, and six months, respectively. By the end of the follow-up period, the average pain scores decreased significantly from 7.09 ± 0.70 to 2.18 ± 1.16 (p < 0.001). The quality of life of patients was significantly improved, and the Uw-Qol of score increased from 1148.63 ± 94.07 to 1269.54 ± 118.25 (p < 0.05). No patient appeared serious complications. The clinical symptoms and quality of life of all patients were significantly improved.</p><p><strong>Conclusion: </strong>Ultrasound-guided percutaneous thermal ablation is a safe and effective minimally invasive method for the treatment of metastatic nodules of abdominal wall, presenting a viable option for patients who are unsuitable for or unwilling to undergo surgery.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"583"},"PeriodicalIF":3.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143762997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimal lymph node yield for long-term survival in elderly patients with right-sided colon cancer: a large population-based cohort study.","authors":"Tianyi Liu, Shuai Jiao, Shan Gao, Yan Shi","doi":"10.1186/s12885-025-13987-3","DOIUrl":"https://doi.org/10.1186/s12885-025-13987-3","url":null,"abstract":"<p><strong>Background: </strong>Although the recommended minimal lymph node yield (LNY) in colon cancer is 12, this standard remains controversial in elderly patients with right-sided colon cancer (RSCC) due to insufficient evidence. This study aims to clarify this issue by assessing the relationship between LNY and long-term survival in elderly patients with RSCC.</p><p><strong>Methods: </strong>Data from the SEER database (split into 7:3 training and testing sets) and patients from the colorectal surgery departments of two tertiary hospitals in China (validation set) were analyzed. Elderly patients with stages I-III RSCC undergoing resection were included. The correlation between LNY and overall survival (OS) was evaluated by a multivariate model and the application of the restricted cubic spline curve (RCS). The odds ratios (ORs) for stage migration and the hazard ratios (HRs) for OS with increased LNY were estimated using Locally Weighted Scatterplot Smoothing (LOWESS), with structural breakpoints identified using the Chow test.</p><p><strong>Results: </strong>The distribution of LNY was similar across the training (median: 18, IQR [14, 23]), testing (median: 18, IQR [14, 23]), and validation (median: 17, IQR [14, 20]) sets. Increasing LNY was associated with significantly improved OS in all datasets (Training set: HR = 0.983; Testing set: HR = 0.981; Validation set: HR = 0.944, all P < 0.001) after adjusting for confounders. Cut-point analysis identified an optimal LNY threshold of 18, validated across datasets, effectively discriminating survival probabilities.</p><p><strong>Conclusions: </strong>A higher LNY is associated with improved survival. Our findings robustly support 18 LNYs as the optimal threshold for assessing the quality of lymph node dissection and prognosis stratification in elderly patients with RSCC.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"590"},"PeriodicalIF":3.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}